10 Best German Stocks To Buy Now

4. Immatics N.V. (NASDAQ:IMTX)

Upside potential as of November 15: 114.20%

Immatics N.V. (NASDAQ:IMTX) is a biotechnology company specializing in the research and development of T-cell redirection immunotherapies for cancer patients. Strategic partnerships with outside pharmaceutical and biotechnology firms generate revenue for the company.

Two therapy types are in the company’s pipeline: antibody-like TCR Bispecifics (TCER) and Engineered Adoptive Cell Therapies (ACTengine). Each therapy is intended to treat patients with distinct solid tumor types and at different stages of the disease, and each has its own benefits.

IMA203 is a lead candidate from Immatics N.V. (NASDAQ:IMTX), which targets solid tumors and has shown encouraging clinical results. Its latest clinical trials, for instance, showed a 55% enhanced overall response rate and a median response duration of more than 13 months, indicating long-lasting effects. This suggests the possibility of developing novel therapies for solid malignancies, including melanoma.

In Q3 2024, total revenue (including revenue from partnership agreements) was $56.7 million, up from $6.6 million in the same quarter the year before. The primary cause of the increase is a one-time revenue related to Bristol Myers Squibb YoY’s termination of the IMA401 partnership.

In Q3 2024,  the overall amount of cash and cash equivalents, along with other financial assets, is $549.2 million, up from $476.8 million in the same period last year. Ongoing research and development efforts partially offset the rise, which was mostly caused by the January 2024 public offering. Immatics N.V. (NASDAQ:IMTX) currently anticipates a cash runway into the second half of 2027 after its $150 million IPO in October 2024. It is among the best German stocks on our list.